Table 5.
Observational studies reporting candidemia associated with COVID-19.
| Characteristics | No. (%) |
|---|---|
| No. of candidemia cases/total number of patients | 360/9451 (3.8) |
| Sex | Male: 162 (45.1) |
| Main underlying diseases | Diabetes mellitus: 91 (25.3) Arterial hypertension: 74 (20.6) Cardiovascular disease: 60 (16.7) Chronic pulmonary disease: 37 (10.3) Obesity: 23 (6.4) |
| COVID-19 treatments | Steroids: 156 (43.4) Tocilizumab: 69 (19.2) |
| No. of patients with central venous catheters | 247/267 (92.5) |
| No. of patients on total parenteral nutrition | 49/229 (21.4) |
| No. of patients on antibiotic therapy | 172/180 (95.6) |
| No. of patients undergoing mechanical ventilation | 227/271 (83.8) |
| Candida species |
C. albicans: 164 (44.4) C. glabrata: 51 (14) C. parapsilosis: 50 (13.8) C. tropicalis: 31 (8.5) C. auris: 20 (5.5) C. dubliniensis: 4 (1.1) Other: 43 (11.8) Total: 363 |
| No. of patients receiving anti-fungal treatment Anti-fungal agents |
190/253 (75) Fluconazole: 38 (20) Anidulafungin: 37 (19.4) Caspofungin: 25 (13.2) Micafungin: 20 (10.5) Fluconazole: 38 (20) Other azoles: 5 (2.6) |
| No. of deaths | 202/270 (74.8) |
Data are absolute numbers (percentage), unless otherwise specified. Abbreviations: ICU, intensive care unit; IQR, interquartile range; TI, tracheal intubation; AMB, amphotericin B.